KALY Initiates Phase Two Cannabis Extract COPD Treatment Study
March 18 2019 - 12:43PM
InvestorsHub NewsWire
Dallas, TX – March 18, 2019 -- InvestorsHub
NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts,
Inc.) (USOTC:
KALY) (“KALY”) today announced Professor Jeffry Osbourn, Ph.D., from the University
of Kentucky and the principal of Biomedical Science Research Group
(BSRG), and KALY CEO Frederick Ferri met last week to coordinate a
phase two study of a pilot treatment of Chronic Obstructive
Pulmonary Disease (COPD) in primates with cannabis extracts
derived from Kali-Extracts patented cannabis extraction
process. A report on the first primate study from Professor
Jeffry Osbourn is coming soon. The primate study adds to
the Kali-Extracts in vitro genomics study, previously announced, to
evaluate the impact of its pharmaceutical grade cannabis extracts
in combination with other therapies on COPD patients. The
World Health Organization estimates 65 million people worldwide are
afflicted with moderate to severe COPD and GlobalData forecasts
that the COPD treatment market will reach $14.1 billion by
2025.
KALY is a health and wellness company set to
generate revenue from its patented cannabis extraction technology
through overlapping go-to-market strategies. In addition
developing pharmaceutical products internally and through
partnerships, KALY is utilizing is patented cannabis extraction
process to develop numerous wellness products both internally and
through partnerships. The company has made recent advances
in partnership with Puration, Inc. (USOTC:
PURA) (“PURA”) developing a CBD extract for infusion into a
beverage at a 25 mg concentration. The first target beverage for
the 25 mg CBD concentrate beverage is a private labeled health
water for Generex Biotechnology (OTCBB:
GNBT).
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024